Treatment of Male Osteoporosis with Bisphosphonates

Osteoporosis in Men

Volumn , Issue , 2010, Pages 667-679

  Giusti, Andrea ^a   Papapoulos, Socrates E ^b  

^a GALLIERA HOSPITAL   (Italy)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882845470     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-374602-3.00054-7     Document Type: Chapter

References (80)

1. Papapoulos S.E. Bisphosphonates for postmenopausal osteoporosis. Primer on the Metabolic Bone Diseases and Disorders of Mineral metabolism 2008, 237-241. American Society for Bone and Mineral Research, Washington, DC. seventh edn. C.J. Rosen (Ed.).
2. Papapoulos S.E. Bisphosphonates: how do they work?. Best Pract. Res. Clin. Endocrinol. Metab. 2008, 22:831-847.
3. Russell R.G.G., Watts N.B., Ebetino F.H., Rogers M.J. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos. Int. 2008, 19:733-759.
4. Gertz B.J., Holland S.D., Kline W.F., et al. Studies of the oral bioavailability of alendronate. Clin. Pharmacol. Ther. 1995, 58:288-298.
5. Cremers S.C., Papapoulos S.E., Gelderblom H., et al. Skeletal retention of bisphosphonate (pamidronate) and its relation to the rate of bone resorption in patients with breast cancer and bone metastases. J. Bone Miner. Res. 2005, 20:1543-1547.
6. Khan S.A., Kanis J.A., Vasikaran S., et al. Elimination and biochemical responses to intravenous alendronate in postmenopausal osteoporosis. J. Bone Miner. Res. 1997, 12:1700-1707.
7. Papapoulos S.E., Cremers S.C. Prolonged bisphosphonate release after treatment in children. N. Engl. J. Med. 2007, 356:1075-1076.
8. Bone H.G., Hosking D., Devogelaer J.P., et al. Alendronate Phase III Osteoporosis Treatment Study Group. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N. Engl. J. Med. 2004, 350:1189-1199.
9. Papapoulos S., Makras P. Selection of antiresorptive or anabolic treatments for postmenopausal osteoporosis. Nat. Clin. Pract. Endocrinol. Metab. 2008, 4:514-523.
10. Roelofs A.J., Thompson K., Gordon S., Rogers M.J. Molecular mechanisms of action of bisphosphonates: current status. Clin. Cancer Res. 2006, 12:6222s-6230s.
11. Valkema R., Vismans F.J., Papapoulos S.E., Pauwels E.K., Bijvoet O.L. Maintained improvement in calcium balance and bone mineral content in patients with osteoporosis treated with the bisphosphonate APD. Bone Miner. 1989, 5:183-192.
12. Ho Y.V., Frauman A.G., Thomson W., Seeman E. Effects of alendronate on bone density in men with primary and secondary osteoporosis. Osteoporos. Int. 2000, 11:98-101.
13. Brumsen C., Papapoulos S.E., Lips P., et al. Daily oral pamidronate in women and men with osteoporosis: a 3-year randomized placebo-controlled clinical trial with a 2-year open extension. J. Bone Miner. Res. 2002, 17:1057-1064.
14. Iwamoto J., Takeda T., Sato Y., Uzawa M. Comparison of the effect of alendronate on lumbar bone mineral density and bone turnover in men and postmenopausal women with osteoporosis. Clin. Rheumatol. 2007, 26:161-167.
15. Gonnelli S., Cepollaro C., Pondrelli C., et al. Bone turnover and the response to alendronate treatment in postmenopausal osteoporosis. Calcif. Tissue Int. 1999, 65:359-364.
16. Lyles K.W., Colón-Emeric C.S., Magaziner J.S., et al. HORIZON Recurrent Fracture Trial. Zoledronic acid and clinical fractures and mortality after hip fracture. N. Engl. J. Med. 2007, 357:1799-1809.
17. Boonen S., Magaziner J., Lyles K., et al. Effect of once-yearly i.v. zoledronic acid in men after hip fracture: results from the HORIZON-Recurrent Fracture Trial. Osteoporos. Int. 2009, 20(Suppl 1):S84.
18. Kanis J.A., Stevenson M., McCloskey E.V., Davis S., Lloyd-Jones M. Glucocorticoid-induced osteoporosis: a systematic review and cost-utility analysis. Health Technol. Assess. 2007, 11:1-231.
19. Saag K.G., Emkey R., Schnitzer T.J., et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. N. Engl. J. Med. 1998, 339:292-299.
20. Adachi J.D., Saag K.G., Delmas P.D., et al. Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial. Arthritis Rheum. 2001, 44:202-211.
21. Cohen S., Levy R.M., Keller M., et al. Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum. 1999, 42:2309-2318.
22. Reid D.M., Hughes R.A., Laan R.F., et al. Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study. J. Bone Miner. Res. 2000, 15:1006-1013.
23. Ringe J.D., Dorst A., Faber H., Ibach K., Sorenson F. Intermittent intravenous ibandronate injections reduce vertebral fracture risk in corticosteroid-induced osteoporosis: results from a long-term comparative study. Osteoporos. Int. 2003, 14:801-807.
24. Adachi J.D., Bensen W.G., Brown J., et al. Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. N. Engl. J. Med. 1997, 337:382-387.
25. Campbell I.A., Douglas J.G., Francis R.M., Prescott R.J., Reid D.M. Research Committee of the British Thoracic Society. Five year study of etidronate and/or calcium as prevention and treatment for osteoporosis and fractures in patients with asthma receiving long term oral and/or inhaled glucocorticoids. Thorax 2004, 59:761-768.
26. Reid D.M., Devogelaer J.P., Saag K., et al. HORIZON investigators. Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet 2009, 373:1253-1263.
27. De Nijs R.N., Jacobs J.W., Lems W.F., et al. STOP Investigators. Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis. N. Engl. J. Med. 2006, 355:675-684.
28. Devogelaer J.P., Goemaere S., Boonen S., et al. Evidence-based guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis: a consensus document of the Belgian Bone Club. Osteoporos. Int. 2006, 17:8-19.
29. Reid D.M., Adami S., Devogelaer J.P., Chines A.A. Risedronate increases bone density and reduces vertebral fracture risk within one year in men on corticosteroid therapy. Calcif. Tissue Int. 2001, 69:242-247.
30. Wallach S., Cohen S., Reid D.M., et al. Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. Calcif. Tissue Int. 2000, 67:277-285.
31. Aris R.M., Lester G.E., Renner J.B., et al. Efficacy of pamidronate for osteoporosis in patients with cystic fibrosis following lung transplantation. Am. J. Respir. Crit. Care Med. 2000, 162:941-946.
32. Bianda T., Linka A., Junga G., et al. Prevention of osteoporosis in heart transplant recipients: a comparison of calcitriol with calcitonin and pamidronate. Calcif. Tissue Int. 2000, 67:116-121.
33. Hommann M., Abendroth K., Lehmann G., et al. Effect of transplantation on bone: osteoporosis after liver and multivisceral transplantation. Transplant. Proc. 2002, 34:2296-2298.
34. Ninkovic M., Love S., Tom B.D., Bearcroft P.W., Alexander G.J., Compston J.E. Lack of effect of intravenous pamidronate on fracture incidence and bone mineral density after orthotopic liver transplantation. J. Hepatol. 2002, 37:93-100.
35. Ippoliti G., Pellegrini C., Campana C., et al. Clodronate treatment of established bone loss in cardiac recipients: a randomized study. Transplantation 2003, 75:330-334.
36. Tauchmanovà L., Selleri C., Esposito M., et al. Beneficial treatment with risedronate in long-term survivors after allogeneic stem cell transplantation for hematological malignancies. Osteoporos. Int. 2003, 14:1013-1019.
37. Shane E., Addesso V., Namerow P.B., et al. Alendronate versus calcitriol for the prevention of bone loss after cardiac transplantation. N. Engl. J. Med. 2004, 350:767-776.
38. Kananen K., Volin L., Laitinen K., Alfthan H., Ruutu T., Välimäki M.J. Prevention of bone loss after allogeneic stem cell transplantation by calcium, vitamin D, and sex hormone replacement with or without pamidronate. J. Clin. Endocrinol. Metab. 2005, 90:3877-3885.
39. Crawford B.A., Kam C., Pavlovic J., et al. Zoledronic acid prevents bone loss after liver transplantation: a randomized, double-blind, placebo-controlled trial. Ann. Intern. Med. 2006, 144:239-248.
40. Grigg A.P., Shuttleworth P., Reynolds J., et al. Pamidronate reduces bone loss after allogeneic stem cell transplantation. J. Clin. Endocrinol. Metab. 2006, 91:3835-3843.
41. Atamaz F., Hepguler S., Akyildiz M., Karasu Z., Kilic M. Effects of alendronate on bone mineral density and bone metabolic markers in patients with liver transplantation. Osteoporos. Int. 2006, 17:942-949.
42. Monegal A., Guañabens N., Suárez M.J., et al. Pamidronate in the prevention of bone loss after liver transplantation: a randomized controlled trial. Transpl. Int. 2009, 22:198-206.
43. Grotz W.H., Rump L.C., Niessen A., et al. Treatment of osteopenia and osteoporosis after kidney transplantation. Transplantation 1998, 66:1004-1008.
44. Fan S.L., Almond M.K., Ball E., Evans K., Cunningham J. Pamidronate therapy as prevention of bone loss following renal transplantation. Kidney Int. 2000, 57:684-690.
45. Giannini S., D'Angelo A., Carraro G., et al. Alendronate prevents further bone loss in renal transplant recipients. J. Bone Miner. Res. 2001, 16:2111-2117.
46. Grotz W., Nagel C., Poeschel D., et al. Effect of ibandronate on bone loss and renal function after kidney transplantation. J. Am. Soc. Nephrol. 2001, 12:1530-1537.
47. Coco M., Glicklich D., Faugere M.C., et al. Prevention of bone loss in renal transplant recipients: a prospective, randomized trial of intravenous pamidronate. J. Am. Soc. Nephrol. 2003, 14:2669-2676.
48. Haas M., Leko-Mohr Z., Roschger P., et al. Zoledronic acid to prevent bone loss in the first 6 months after renal transplantation. Kidney Int. 2003, 63:1130-1136.
49. Jeffery J.R., Leslie W.D., Karpinski M.E., Nickerson P.W., Rush D.N. Prevalence and treatment of decreased bone density in renal transplant recipients: a randomized prospective trial of calcitriol versus alendronate. Transplantation 2003, 76:1498-1502.
50. El-Agroudy A.E., El-Husseini A.A., El-Sayed M., Mohsen T., Ghoneim M.A. A prospective randomized study for prevention of postrenal transplantation bone loss. Kidney Int. 2005, 67:2039-2045.
51. Nayak B., Guleria S., Varma M., et al. Effect of bisphosphonates on bone mineral density after renal transplantation as assessed by bone mineral densitometry. Transplant. Proc. 2007, 39:750-752.
52. Torregrosa J.V., Fuster D., Pedroso S., et al. Weekly risedronate in kidney transplant patients with osteopenia. Transpl. Int. 2007, 20:708-711.
53. Lan G., Peng L., Xie X., Peng F., Wang Y., Yu S. Alendronate is effective to treat bone loss in renal transplantation recipients. Transplant. Proc. 2008, 40:3496-3498.
54. Trabulus S., Altiparmak M.R., Apaydin S., Serdengecti K., Sariyar M. Treatment of renal transplant recipients with low bone mineral density: a randomized prospective trial of alendronate, alfacalcidol, and alendronate combined with alfacalcidol. Transplant. Proc. 2008, 40:160-166.
55. Stein E., Ebeling P., Shane E. Post-transplantation osteoporosis. Endocrinol. Metab. Clin. N. Am. 2007, 36:937-963.
56. Amorosa V., Tebas P. Bone disease and HIV infection. Clin. Infect. Dis. 2006, 42:108-114.
57. Triant V.A., Brown T.T., Lee H., Grinspoon S.K. Fracture prevalence among human immunodeficiency virus (HIV)-infected versus non-HIV-infected patients in a large US healthcare system. J. Clin. Endocrinol. Metab. 2008, 93:3499-3504.
58. McComsey G.A., Kendall M.A., Tebas P., et al. Alendronate with calcium and vitamin D supplementation is safe and effective for the treatment of decreased bone mineral density in HIV. AIDS 2007, 21:2473-2482.
59. Bolland M.J., Grey A.B., Horne A.M., et al. Annual zoledronate increases bone density in highly active antiretroviral therapy-treated human immunodeficiency virus-infected men: a randomized controlled trial. J. Clin. Endocrinol. Metab. 2007, 92:1283-1288.
60. Huang J., Meixner L., Fernandez S., McCutchan J.A. A double-blinded, randomized controlled trial of zoledronate therapy for HIV-associated osteopenia and osteoporosis. AIDS 2009, 23:51-57.
61. Gaudio A., Morabito N., Xourafa A., et al. Bisphosphonates in the treatment of thalassemia-associated osteoporosis. J. Endocrinol. Invest. 2008, 31:181-184.
62. Orwoll E., Ettinger M., Weiss S., et al. Alendronate for the treatment of osteoporosis in men. N. Engl. J. Med. 2000, 343:604-610.
63. Ringe J.D., Dorst A., Faber H., Ibach K. Alendronate treatment of established primary osteoporosis in men: 3-year results of a prospective, comparative, two-arm study. Rheumatol. Int. 2004, 24:110-113.
64. Ringe J.D., Farahmand P., Faber H., Dorst A. Sustained efficacy of risedronate in men with primary and secondary osteoporosis: results of a 2-year study. Rheumatol. Int. 2009, 29:311-315.
65. Boonen S., Orwoll E., Wenderoth D., Stoner K., Eusebio R., Delmas P. Once-weekly risedronate in men with osteoporosis: results of a 2-year, placebo-controlled, double-blind, multicenter study. J. Bone Miner. Res. 2009, 24:719-725.
66. Liberman U.A., Weiss S.R., Bröll J., et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N. Engl. J. Med. 1995, 333:1437-1443.
67. Bone H.G., Greenspan S.L., McKeever C., et al. Alendronate and estrogen effects in postmenopausal women with low bone mineral density. Alendronate/Estrogen Study Group. J. Clin. Endocrinol. Metab. 2000, 85:720-726.
68. Harris S.T., Watts N.B., Genant H.K., et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. J. Am. Med. Assoc. 1999, 282:1344-1352.
69. Reginster J., Minne H.W., Sorensen O.H., et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos. Int. 2000, 11:83-91.
70. Sawka A.M., Papaioannou A., Adachi J.D., Gafni A., Hanley D.A., Thabane L. Does alendronate reduce the risk of fracture in men? A meta-analysis incorporating prior knowledge of anti-fracture efficacy in women. BMC Musculoskelet. Disord. 2005, 6:39-46.
71. Black D.M., Cummings S.R., Karpf D.B., et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996, 348:1535-1541.
72. Abrahamsen B., Nielsen M.F., Eskildsen P., Andersen J.T., Walter S., Brixen K. Fracture risk in Danish men with prostate cancer: a nationwide register study. BJU Int. 2007, 100:749-754.
73. Higano CS. Androgen-deprivation-therapy-induced fractures in men with nonmetastatic prostate cancer: what do we really know?. Nat. Clin. Pract. Urol. 2008, 5:24-34.
74. Smith M.R., Eastham J., Gleason D.M., Shasha D., Tchekmedyian S., Zinner N. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J. Urol. 2003, 169:2008-2012.
75. Michaelson M.D., Kaufman D.S., et al. Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer. J. Clin. Oncol. 2007, 25:1038-1042.
76. Greenspan S.L., Nelson J.B., Trump D.L., et al. Skeletal health after continuation, withdrawal, or delay of alendronate in men with prostate cancer undergoing androgen-deprivation therapy. J. Clin. Oncol. 2008, 26:4426-4434.
77. Epstein S., Inzerillo A.M., Caminis J., Zaidi M. Disorders associated with acute rapid and severe bone loss. J. Bone Miner. Res. 2003, 18:2083-2094.
78. Sato Y., Iwamoto J., Kanoko T., Satoh K. Risedronate sodium therapy for prevention of hip fracture in men 65 years or older after stroke. Arch. Intern. Med. 2005, 165:1743-1748.
79. Sato Y., Honda Y., Iwamoto J. Risedronate, and ergocalciferol prevent hip fracture in elderly men with Parkinson disease. Neurology 2007, 68:911-915.
80. Zehnder Y., Risi S., Michel D., et al. Prevention of bone loss in paraplegics over 2 years with alendronate. J. Bone Miner. Res. 2004, 19:1067-1074.